T cell non-Hodgkin lymphomas are a heterogeneous group of highly aggressive malignancies with poor clinical outcomes 1 . T cell lymphomas originate from peripheral T cells and are frequently characterized by genetic gain-of-function variants in T cell receptor (TCR) signalling molecules [1] [2] [3] [4] . Although these oncogenic alterations are thought to drive TCR pathways to induce chronic proliferation and cell survival programmes, it remains unclear whether T cells contain tumour suppressors that can counteract these events. Here we show that the acute enforcement of oncogenic TCR signalling in lymphocytes in a mouse model of human T cell lymphoma drives the strong expansion of these cells in vivo. However, this response is short-lived and robustly counteracted by cell-intrinsic mechanisms. A subsequent genome-wide in vivo screen using T cell-specific transposon mutagenesis identified PDCD1, which encodes the inhibitory receptor programmed death-1 (PD-1), as a master gene that suppresses oncogenic T cell signalling. Mono-and bi-allelic deletions of PDCD1 are also recurrently observed in human T cell lymphomas with frequencies that can exceed 30%, indicating high clinical relevance. Mechanistically, the activity of PD-1 enhances levels of the tumour suppressor PTEN and attenuates signalling by the kinases AKT and PKC in pre-malignant cells. By contrast, a homo-or heterozygous deletion of PD-1 allows unrestricted T cell growth after an oncogenic insult and leads to the rapid development of highly aggressive lymphomas in vivo that are readily transplantable to recipients. Thus, the inhibitory PD-1 receptor is a potent haploinsufficient tumour suppressor in T cell lymphomas that is frequently altered in human disease. These findings extend the known physiological functions of PD-1 beyond the prevention of immunopathology after antigen-induced T cell activation, and have implications for T cell lymphoma therapies and for current strategies that target PD-1 in the broader context of immunooncology.
T cell non-Hodgkin lymphomas are a heterogeneous group of highly aggressive malignancies with poor clinical outcomes 1 . T cell lymphomas originate from peripheral T cells and are frequently characterized by genetic gain-of-function variants in T cell receptor (TCR) signalling molecules [1] [2] [3] [4] . Although these oncogenic alterations are thought to drive TCR pathways to induce chronic proliferation and cell survival programmes, it remains unclear whether T cells contain tumour suppressors that can counteract these events. Here we show that the acute enforcement of oncogenic TCR signalling in lymphocytes in a mouse model of human T cell lymphoma drives the strong expansion of these cells in vivo. However, this response is short-lived and robustly counteracted by cell-intrinsic mechanisms. A subsequent genome-wide in vivo screen using T cell-specific transposon mutagenesis identified PDCD1, which encodes the inhibitory receptor programmed death-1 (PD-1), as a master gene that suppresses oncogenic T cell signalling. Mono-and bi-allelic deletions of PDCD1 are also recurrently observed in human T cell lymphomas with frequencies that can exceed 30%, indicating high clinical relevance. Mechanistically, the activity of PD-1 enhances levels of the tumour suppressor PTEN and attenuates signalling by the kinases AKT and PKC in pre-malignant cells. By contrast, a homo-or heterozygous deletion of PD-1 allows unrestricted T cell growth after an oncogenic insult and leads to the rapid development of highly aggressive lymphomas in vivo that are readily transplantable to recipients. Thus, the inhibitory PD-1 receptor is a potent haploinsufficient tumour suppressor in T cell lymphomas that is frequently altered in human disease. These findings extend the known physiological functions of PD-1 beyond the prevention of immunopathology after antigen-induced T cell activation, and have implications for T cell lymphoma therapies and for current strategies that target PD-1 in the broader context of immunooncology.
Recent integrated molecular studies of human T cell lymphomas have identified activating mutations in signalling molecules that regulate TCR pathways as a hallmark of most T cell non-Hodgkin lymphoma (NHL) subtypes [1] [2] [3] [4] [5] [6] . These alterations affect antigen receptor proximal regulators, PI3K elements that engage the AKT pathway, mediators of antigen-induced NF-κ B activation, such as PKCs and CARD11, and various other factors [1] [2] [3] [4] [5] [6] . A specific chromosomal translocation that is recurrently detected in human peripheral T cell lymphoma cases is t(5;9)(q33;q22) 7, 8 , which fuses the antigen receptor kinase genes ITK and SYK. The chimaeric ITK-SYK protein exhibits constitutive tyrosine kinase activity and enforces the oncogenic activations of TCR pathways via the activation of PLCγ , PI3K/AKT signalling and PKC/NF-κ B 8 . We used this fusion protein to explore experimentally the pathomechanisms of T cell lymphomagenesis, a paradigm that has been successfully exploited in several other haematopoietic malignancies with recurrent chromosomal translocations 9 . To generate a genetically tractable model of human T cell NHL, we introduced a patient-derived ITK-SYK together with an enhanced green fluorescent protein (eGFP) cDNA into the mouse Rosa26 locus preceded by a loxP-flanked STOP cassette (LSL; Rosa26 LSL-ITK-SYK mice) 8 . Crossing Rosa26 LSL-ITK-SYK mice to CD4-Cre transgenic mice for T-cell-specific ITK-SYK expression induced fully penetrant aggressive T cell lymphomas in the offspring (ITK-SYK CD4-cre mice) that exhibited molecular, clinical and pathological features of the human disease 8 (Extended Data Fig. 1a-c) . Although the constitutively active CD4-Cre transgene drives continuous expression of ITK-SYK in millions of polyclonal T cells, the final lymphomas are typically clonal 8 (Extended Data Fig. 1d ). In contrast to polyclonal T cells from young ITK-SYK CD4-cre mice, these clonal lymphoma cells transmit the disease to recipient mice (Extended Data Fig. 1e ), indicating that in addition to ITK-SYK expression, the cells possess genetic alterations that promote malignancy.
To assess the evolution of these cancers in a controlled manner, we crossed Rosa26 LSL-ITK-SYK mice with animals that allow tamoxifeninducible Cre activation in CD4 + T cells (CD4-CreER T2 mice) 10 . We triggered single pulses of Cre activity in subsets of lymphocytes in the progeny (ITK-SYK CD4-creERT2 mice) ( Fig. 1a-c) . ITK-SYK and eGFP expression in individual lymphocytes led to a rapid expansion of these cells in vivo (Fig. 1a) . The maximal frequencies of ITK-SYK + CD4 + T cells increased with increasing doses of tamoxifen (r = 0.99). However, after this expansion phase, the ITK-SYK + compartments again contracted (Fig. 1a) . To characterize these two phases, we again induced ITK-SYK expression in T cells in vivo and then sorted recombined CD4 + T cells by flow cytometry for an in vitro RNA sequencing (RNA-seq) analysis (Fig. 1b) . Gene set enrichment analysis (GSEA) revealed enrichment in the signatures 'Ishida E2F targets' 11 , 'hallmark G2M checkpoint' 12 and 'Whitfield cell cycle literature' 13 in the ITK-SYK-expressing cells at day 4 compared with that of naive CD4 + T cells, demonstrating a highly proliferative phenotype. However, at day 7, the proliferative signatures were significantly downregulated (P < 0.01) along with the declining ITK-SYK + T cell numbers in vivo, indicating that T cells possess tumour-suppressive mechanisms that can counteract oncogenic T cell signalling within days. Nevertheless, within one year, two out of the three mice that received the highest dose of tamoxifen (1 mg) developed ITK-SYK-expressing CD4 + T cell lymphomas (Fig. 1c) , with organ infiltration by malignant lymphoblasts (Extended Data Fig. 1f-h ), which demonstrated that the tumour-suppressive pathways can be disrupted. Because the onset of these lymphomas was correlated with the initial frequency of the ITK-SYK-expressing T cells ( Fig. 1c ; P = 0.005), these tumour-enabling secondary events are presumably stochastic in nature.
To reveal the mechanisms that enable full T cell transformation after oncogenically enforced TCR signalling, we designed a genome-wide forward genetic screen (Fig. 2a) using the piggyBac (PB) transposition system for in vivo mutagenesis 14, 15 . To achieve spatially restricted LSL-ITK-SYK mice to CD4-Cre mice and animals that conditionally express the piggyBac transposase from the Rosa26 locus (Rosa26
LSL-PB
), and to ATP2-H32 transgenic mice that contain mutagenic ATP transposon cassettes that could be mobilized by piggyBac 15, 16 . The quadruple-transgenic progeny developed accelerated T cell lymphomas after transposon mobilization (Extended Data Fig. 2a-c) . The integration sites were recovered from flow cytometry-sorted eGFP + cancer cells by multiplexed quantitative insertion-site sequencing (QiSeq) 15 followed by statistical analyses 17 to identify the genomic regions that were more frequently hit by transposons than expected by chance (Fig. 2a) . Remarkably, the top ranking common insertion site (CIS; genomic region with the highest transposon insertion density) with the highest significance (P = 0.87 × 10 −31 ) across the genome was located at the Pdcd1 locus that encodes the inhibitory PD-1 receptor 18 ( Fig. 2b and Extended Data Fig. 2e ). These insertions did not significantly co-cluster with common insertions in other loci and resulted in Pdcd1-transposon fusion transcripts (Extended Data Fig. 2f ). Some cancers had several Pdcd1 insertions that probably reflected bi-allelic inactivation and/or local transposon hopping with gene trapping in subclones. Lymphomas with Pdcd1 transposon insertions exhibited a reduction in or a lack of PD-1 protein and Pdcd1 mRNA expression ( Fig. 2c and Extended Data Fig. 2d ).
PD-1 restricts antigen-induced TCR responses at tolerance checkpoints with persistent antigenic stimulation to prevent autoimmunity 18 , and has received considerable attention because it limits antigen-driven T cell proliferation and survival in suppressive microenvironments in cancer and chronic infection 19 . Our genetic screen indicated that PD-1 might also possess unrecognized functions as a tumour suppressor in T cell lymphoma. To study potential PDCD1 alterations in human T cell lymphoma, we performed a meta-analysis of five published studies [2] [3] [4] [5] [6] . Notably, we found genomic PDCD1 alterations in 36 out of 158 cases (23%) (Extended Data Table 1 ). The predominant mutation type was copy number aberration (33 cases). Among these, focal deletions with mono-or bi-allelic PDCD1 loss were prominent (Fig. 2d , Extended Data Table 1 and Extended Data Fig. 3a, b) . The highest proportion of homo-or heterozygous PDCD1-deleted cases (36%, 13 out of 36) was found in a group of patients with advanced stage IV cutaneous T cell lymphoma 3 (Extended Data Table 1 ). A single case with PDCD1 genomic gain exhibited defective PDCD1 mRNA expression (Extended Data Fig. 3a) . In light of our genetic screen, these frequent homo-or heterozygous PDCD1 deletions in human T cell NHL strongly suggest that PD-1 is functionally relevant in the pathogenesis of lymphoma.
In normal T cells, PD-1 expression is upregulated after TCR ligation 19 , and PD-1 subsequently provides feedback for the prevention of autoimmunity. To investigate whether oncogenic T cell signals + T cells (CD4 naive) and ITK-SYK T cells at 4 and 7 days (d) after tamoxifen injection. The colour intensity of the circles denotes the significance level (false discovery rate, FDR); the circle diameter reflects the normalized enrichment score (NES). Blue/red indicates the group in which a signature was positively enriched; n = 3 biological replicates for each group. NS, not significant. c, Cohorts shown in a were followed over one year (n = 3 biological replicates per dose). Data in the dashed box correspond to the data in a. Dagger symbols indicate animals that had to be euthanized because of lymphoma. P value determined by Fisher's exact test, performed on pooled data from two independent experiments. Representative data from one experiment are shown.
can also induce PD-1 expression, we introduced ITK-SYK variants into Jurkat T cells 8 . ITK-SYK signalling drives PD-1 expression in a kinase-dependent manner (Extended Data Fig. 4a ). In transduced primary human CD4 + T cells, we also detected the ITK-SYK kinasemediated upregulation of PD-1 expression (Extended Data Fig. 4b) . Likewise, acute ITK-SYK expression in primary CD4 + T cells from tamoxifen-treated ITK-SYK CD4-creERT2 mice also drives robust PD-1 protein and mRNA expression (Fig. 3a, b and Extended Data Fig. 4c) . Moreover, the analysis of human T cell NHL samples (n = 50) 2, 6 , which did or did not exhibit the activation of the gene signature 'GO antigen receptor-mediated signalling pathway' (195 genes), demonstrated that the aberrant activation of TCR signalling pathways was correlated with significantly upregulated PDCD1 mRNA expression in these tumours (Fig. 3c, d ). In addition, within this patient group, loss of one or two PDCD1 alleles led to significantly reduced or completely absent PDCD1 mRNA expression (Fig. 3e) . Thus, PDCD1 expression is upregulated after oncogenic T cell signalling in mouse and human cells, and the loss of the PDCD1 locus in human T cell NHL impairs PDCD1 mRNA expression.
PD-1 ligation dampens physiological antigen-mediated T cell activation by enhancing levels of the the tumour suppressor phosphatase PTEN 20 and attenuating the PI3K/AKT 21 and PKCθ /NF-κ B pathways 22 . Because these two cascades are crucial for lymphomagenesis, we tested whether they were sensitive to PD-1 ligation after oncogene induction. We activated ITK-SYK in vivo by injecting tamoxifen into ITK-SYK CD4-creERT2 mice, isolated CD4 + cells, stimulated them with programmed death-ligand 1 (PD-L1) and subsequently performed an intracellular Phosflow analysis. The engagement of PD-1 increased PTEN protein levels and attenuated the AKT and PKCθ activities in pre-malignant ITK-SYK-expressing cells (Fig. 3f) . Thus, oncogenic T cell signalling upregulates PD-1 expression, and PD-1 functions to suppress oncogenic effector pathways.
To study the oncogene-PD-1 loop in tumour suppression in vivo, we crossed the Rosa26 LSL-ITK-SYK and CD4-CreER T2 alleles on a PD-1-deficient background 23 and triggered ITK-SYK expression via tamoxifen in the offspring. As previously observed, the marked expansion of ITK-SYK-expressing eGFP + T cells was robustly counter-regulated in the presence of PD-1 (Fig. 4a) . In sharp contrast, without PD-1, the ITK-SYK + T cells expanded without restriction, and all tamoxifen-treated ITK-SYK ; Pdcd1 −/− animals had to be euthanized after only one week because of a strong accumulation of lymphoblastoid ITK-SYK + PD-1 − CD4 + T cells in the lymphoid tissues and invasive growth with a noncohesive pattern into the solid organs ( Fig. 4a and Extended Data Fig. 5a-c) . Upon transplantation, these ITK-SYK + PD-1 − CD4 + T cells continued to expand invasively and transmitted the lethal disease to recipients, demonstrating that these cells were fully transformed malignant lymphocytes ( Fig. 4b and Extended Data Fig. 5d-g ). In parallel, we incubated CD4 + T cells from ) robustly expanded and induced lethal infiltrative lymphomas that could be serially transplanted into syngeneic animals (Extended Data Fig. 6g-j) . Thus, the absence of PD-1 in peripheral T cells enables an appropriate oncogenic signal to create an aggressive cancer directly.
Because mono-allelic deletions are the most common type of PDCD1 alteration in human T cell NHL (see Fig. 2d , Extended Data Table 1 and Extended Data Fig. 3b) , we also treated heterozygous ITK-SYK ;Pdcd1 +/− mice with tamoxifen. All heterozygous ITK-SYK ;Pdcd1
+/− mice succumbed to invasive transplantable lymphomas after tamoxifen injection ( Fig. 4c and Extended Data Fig. 7a-j) , establishing PD-1 as a haploinsufficient tumour suppressor.
The inhibition of the PD-1-PD-L1 interaction with antibodies against PD-1 or PD-L1 is heavily exploited in the clinic to activate T cell immunity against several cancer cell types 25 . Therefore, we next treated ITK-SYK CD4-creERT2 mice with checkpoint inhibitors (anti-PD-L1 or anti-PD-1 antibodies) after tamoxifen induction (Fig. 4d-f and Extended Data Fig. 8a-c, e) . Notably, similar to a genetic deletion of PD-1, anti-PD-L1 treatment beginning one day after tamoxifen induction led to an immediate proliferation of invasive ITK-SYK + T cells (Fig. 4d, e and Extended Data Fig. 8a-c) . Likewise, the treatment of ITK-SYK CD4-creERT2 mice with anti-PD-L1 or anti-PD-1 antibodies during the contraction phase of the ITK-SYK + cell compartment (10 days after tamoxifen treatment) also induced lethal lymphoproliferation ( Fig. 4f and Extended Data Fig. 8e ). However, these Letter reSeArCH
cells were unable to transmit the disease when transplanted into nonantibody-treated recipients (Extended Data Fig. 8d ). Thus, although these checkpoint inhibitors accelerate the growth of T cells with oncogenically sensitized TCR pathways, their pharmacological effects are only transient in contrast to the effect of T cell intrinsic deletion of the Pdcd1 gene.
We demonstrated above that the ligation of PD-1 enhances PTEN levels and attenuates PI3K/AKT and PKCθ function after ITK-SYK signalling (see Fig. 3f ). PD-1 signalling in a PD-1-transduced human lymphoma cell line also enhances levels of PTEN and attenuates signalling by PI3K/AKT and PKCθ (Extended Data Fig. 9a-c) . Consistently, in PD-1-deficient ITK-SYK + mouse lymphomas, levels of PTEN are reduced and the activity of AKT and PKCθ is enhanced (Fig. 4g) , suggesting that PDCD1 deletions promote tumorigenesis, at least in part, via these mechanisms. To study the functional relevance of PI3K/AKT enforcement, we incubated PD-1-deficient lymphoma cells in vitro with the PI3K inhibitor idelalisib, which is currently undergoing clinical development for selected B cell malignancies 26 . Inhibition of PI3K downregulated AKT activity and induced the death of ITK-SYK + PD-1 − lymphoma cells (Extended Data Fig. 9d ). Finally, we treated mice that contained ITK-SYK + PD-1 − lymphomas with idelalisib in vivo. PI3K inhibition significantly extended the lifespan of these mice, demonstrating that the activity of PI3K/AKT signalling is crucial for lymphomas with Pdcd1 deletion (Fig. 4h and Extended Data Fig. 9e ).
In conclusion, our studies establish PD-1 as a powerful haploinsufficient tumour suppressor in T cell lymphoma. Thus, PD-1 not only functions to prevent autoimmunity after chronic antigen exposure and physiological TCR ligation, but also unexpectedly counteracts oncogenic T cell signalling pathways within precancerous cells. The deficiency in PD-1 in T cell lymphoma promotes PI3K/AKT activity, and our preclinical data suggest PI3K inhibitors as candidate drugs for the treatment of these tumours. Checkpoint blockade with anti-PD-1 or anti-PD-L1 antibodies to relieve T cell inhibition in the tumour microenvironment 27 is a revolutionary treatment of several malignancies 25 and is currently being explored in T cell NHL. Our findings that these checkpoint inhibitors can accelerate and/or reactivate T cell clones with oncogenically activated TCR pathways indicate the need for special consideration when using these inhibitors in patients with T cell NHL. In addition, new clinical trials using CRISPR-Cas9-mediated gene editing to disrupt the PDCD1 locus bi-allelically in peripheral T cells of patients with cancer are being initiated with the aim of enhancing anti-tumour immune responses 28 . Reports have suggested that these treatments could trigger autoimmune reactions 28 . Our data demonstrating that a suitable oncogenic hit on PD-1-deficient T cells is sufficient for their direct malignant transformation puts additional caution on these gene-editing approaches.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. −/− mice were backcrossed on a C57BL/6 genetic background. All animal experiments were performed according to local guidelines (Regierung von Oberbayern, Munich, Germany). Mice were euthanized if they exhibited signs of lymphoma (lymph node enlargement, palpable tumour, laboured breathing, ascites) or if they lost 20% or more of their body weight. None of the approved thresholds was exceeded at any time. Flow cytometry. Flow cytometric analyses were performed using standard protocols. Primary cell suspensions from the spleen, lymph nodes or peripheral blood were directly labelled. Single-cell suspensions from the liver, kidney or lung were first purified by Percoll (17089101, GE Healthcare) gradient centrifugation. Fluorescently labelled antibodies against the following surface proteins were used for staining mouse cells: TCRβ (APC/Cy7-labelled anti-mouse TCRβ chain antibody, 10922), CD4 (Pacific blue-labelled anti-mouse CD4 antibody, 100428), CD44 (PE-labelled anti-mouse/human CD44 antibody, 103008), and PD-1 (APC-labelled anti-mouse CD279 (PD-1) antibody, 135210). For human cells, the following antibodies were used: PD-1 (APC-labelled anti-human CD279 (PD-1) antibody, 329908), CD3 (PE/Cy7-labelled anti-human CD3 antibody, 300420) and PD-L1 (PE-labelled anti-human CD274 (B7-H1, PD-L1) antibody, 329706). Fc receptor blocking was performed with anti-CD16/32 antibodies (101320 or 422302). All antibodies were purchased from BioLegend. The data were acquired using a FACSCanto II flow cytometer (Becton Dickinson). FlowJo software (FlowJo LLC) was used for data analyses. GeneScan analysis of TCR gene rearrangements. Genomic DNA was extracted (DNeasy, Qiagen) from magnetically purified (130104454, Miltenyi Biotec) CD4 + T cells from C57BL/6 mice (control), young ITK-SYK CD4-cre mice and lymphoma-bearing ITK-SYK CD4-cre mice. GeneScan analysis to detect TCR gene rearrangements was performed as previously described 8 . In summary, VDJ rearrangements of the TCRβ and TCRγ loci were amplified via five PCR reactions with 26 primers in total, with three primers labelled with 5′ -FAM fluorochromes. Fluorochrome-labelled PCR products were then size-separated and scanned via capillary electrophoresis. Induction of spontaneous ITK-SYK expression in peripheral T cells. Tamoxifen (T5648, Sigma-Aldrich) was dissolved in pure ethanol (with heating) and subsequently diluted in migliol (3274, Caesar & Loretz) to a final concentration of 10 mg ml −1 . To induce the expression of ITK-SYK in a small fraction of peripheral CD4 + T cells, ITK-SYK , ITK-SYK ;Pdcd1 +/− or ITK-SYK ;Pdcd1 −/− mice were given tamoxifen at the indicated doses via intraperitoneal injection. RNA. For the RNA-seq experiments, ITK-SYK CD4-creERT2 mice were given single intraperitoneal injections of 1 mg tamoxifen per mouse (T5648, Sigma-Aldrich). Forty-eight hours after injection, the spleens were obtained; the single-cell suspensions were subjected to CD4 + T cell purification by magnetic depletion (130104454, Miltenyi Biotec), and the cells were then cultured in vitro. At the indicated time points, the T cells were FACS-sorted (FACSAria, Becton Dickinson) again for viability and eGFP expression. Total RNA was extracted from approximately 100,000 cells using spin columns (RNeasy Micro Plus Kit, Qiagen). Library preparation was performed from 1 ng total RNA with the SMART-Seq v2 Ultra Low Input RNA Kit (Takara Bio), and SE-50 bp sequencing was performed on Illumina HiSeq2000 machines (Illumina). Read alignment to the mm10 genome and transcriptome assembly was performed using HISAT2 30 
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+ T cells. Genomic DNA was extracted using spin columns. The transposon insertion-sites were recovered using QiSeq, a splinkerette-PCR-based method for semiquantitative insertion-site sequencing 15, 17 . Bioinformatics data processing, mapping of sequence reads and statistical analyses to identify CISs using TAPDANCE were performed as described earlier 15, 17 . The CISs that were also detected in the data from control animals without the ITK-SYK transgene were excluded from analysis. Genomic PDCD1 alterations in human T cell lymphoma. PubMed and Google Scholar were searched for published studies on human T cell malignancies that included whole-genome sequencing, whole-exome sequencing or targeted sequencing data. The supplementary data from the identified studies were searched for single nucleotide variants, small indels and CNAs that affect the PDCD1 locus. Whole-genome sequencing data (aligned BAM files, 47 tumour-normal pairs) 2 were downloaded from the European Genome-phenome Archive with permission. Whole-exome sequencing data (aligned BAM files, 34 tumour-normal pairs) 6 were downloaded from the Sequence Read Archive (accession PRJNA285408). The BAM files were subjected to a copy number analysis using Control-FREEC 36 . The copy numbers were calculated for each sample in windows of 3 kb with steps of 1 kb using tumour and corresponding normal samples as inputs. Breakpoint analysis, segmentation and absolute copy number calling were performed with Control-FREEC. The resulting segments and copy number ratios (tumour/normal) were transformed to a log 2 scale and plotted for all tumours along chromosome 2 for visual inspection. GSVA and PDCD1 FPKM analyses in human T cell lymphoma. RNA-seq data of patients with T cell NHL were downloaded from the Sequence Read Archive (accession PRJNA285408) 6 and the European Genome-phenome Archive
2
. Reads were extracted in fasta format from .sra or .bam files and aligned to the hg19 genome with HISAT2 30 and processed with StringTie 31 and Ballgown
32
. All samples with available genomic data (WES or WGS) were included in the analysis. Using GSVA 37 for each sample, an enrichment score was calculated based on the gene set 'GO antigen receptor-mediated signalling pathway' (195 genes) from the MSigDB database: 28 out of 50 samples that were identified as positive for the signature were included in the subsequent analysis. FPKM values for PDCD1 were extracted and statistically compared based on the enrichment score and the PDCD1 copy number status as indicated in the figure legend. Cloning. To generate the PD-1 vector, first, the 3′ LTR of the lentiGuide-Puro Plasmid (52963, Addgene) was replaced by an HIV/MSCV hybrid LTR as described 38 . The LTR-modified backbone and the central polypurine tract (cPPT) sequence were then amplified with the BsmBI restriction site-containing oligos BBf, BBr or CPPTf and CPPTr. Finally, the PDCD1 cDNA was cloned together with an IRES-GFP and a cPPT sequence into the modified backbone via Golden Gate Assembly using the PDCD1f and PDCD1r primers for the cDNA and the IRESGFPf and IRESGFPr primers for the IRES-GFP sequence. The mutant PD-1 YFYF plasmid was subsequently generated using sequential site-directed mutagenesis with the Y223F and Y248F primer pairs. The oligonucleotide sequences are listed in Supplementary Table 2 . Cell culture. T cells were cultured in RPMI-1640 medium containing 20% FCS in the case of primary cells, 10% FCS in the case of HuT 78 T-cell NHL cells 39 or 5% FCS in the case of Jurkat-Eco T cells. To culture the Phoenix-Eco and PhoenixAmpho packaging cells, we used DMEM with 10% FCS. HEK293FT cells were cultured in 5% FCS containing DMEM. The HuT 78 cell line was authenticated at the DSMZ via STR profiling (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures). Otherwise, no authentication of the cell lines was performed. All cell lines were routinely tested for mycoplasma infection.
For the generation of dendritic cells, Ficoll (Ficoll-Paque PLUS, 17144002, GE Healthcare) gradient-separated PBMCs from healthy donors were magnetically enriched for monocytes (130050201, Miltenyi Biotec). Next, the cells were cultured for six days in the presence of recombinant IL-4 (20 ng ml 
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All human PBMCs were collected from healthy donors with informed consent according to the protocols approved by the Institutional Review Boards. The study protocol was approved by the local ethics committee (Ethics Committee of the Medical Faculty, Klinikum rechts der Isar, Technical University of Munich, Germany).
For the in vitro experiments using idelalisib (CAL-101, GS-1101, PI3Kδ inhibitor; S2226, Selleckchem), the inhibitor was dissolved in dimethylsulfoxide (DMSO), and the cell culture medium was supplemented with the indicated concentration of the compound or DMSO (as a control). Retroviral infections. Generation of ecotropic viral particles containing GFP, ITK-SYK or kinase-defective ITK-SYK constructs and infection of Jurkat-Eco cells were performed as previously described 8 . To generate amphotropic retrovirus, Phoenix-Ampho cells were grown in 15-cm dishes and transfected using FuGENE (Promega) with 10 μ g ITK-SYK or kinase-defective ITK-SYK construct 8 . The media was changed 8 h after transfection. The viral supernatant was collected 36 h after transfection, passed through a 0.45-μ m filter and used fresh, or snap-frozen for later. Activated primary human CD4 T cells were spinfected with RetroNectincoated (Takara Bio) 6-well plates (5 mg ml −1 ). For the production of lentiviral particles, we used HEK293FT cells. FuGENE-based transfection was performed with 17 μ g pCMV delta R8.2, 10 μ g pHCMV-10A1 and 10 μ g PD-1 or PD-1 YFYF. HuT 78 cells were infected with the lentivirus on RetroNectin-coated 6-well plates (5 mg ml , purified anti-human CD3 antibody, 300332, BioLegend), soluble anti-CD28 antibodies (2 μ g ml
, purified anti-human CD28 antibody, 302934, BioLegend) and 10 ng ml −1 IL-2 (20002, Peprotech). After 48 h, the cells were infected with retroviruses. Five days later, the T cells were stimulated again with 2 μ g ml −1 soluble anti-CD28 (302934, BioLegend) antibodies and analysed for PD-1 expression by flow cytometry.
Transplantation experiments. For ITK-SYK
CD4-cre transplantation experiments, splenocytes from donor mice were obtained and single-cell suspensions were FACS-sorted for eGFP expression. Subsequently, 3 × 10 6 sorted cells were intravenously injected into C57BL/6 recipient mice.
For transplantation experiments into NSG mice, splenocytes from donor mice were obtained on day 5 or 7 after tamoxifen induction, subjected to CD8 T cell depletion (11447D, Thermo Fisher Scientific) and then injected intravenously into NSG mice.
For transplantation experiments without Cre transgenes, splenocytes from Rosa26 LSL-ITK-SYK and Rosa26
LSL-ITK-SYK
;Pdcd1 −/− mice were collected, and the CD4 + T cells were purified and subsequently incubated for 1 h in serum-free medium (31985062, Thermo Fisher Scientific) supplemented with 1 μ M recombinant TAT-Cre protein (EG1001, Excellgen). After extensive washing, the cells were intravenously injected into C57BL/6 recipients. For transplantation into secondary C57BL/6 recipient mice, the spleens from diseased primary recipients were collected, FACS-sorted for eGFP expression, washed and intravenously injected (1 × 10 5 cells per recipient) into wild-type C57BL/6 mice. In vivo PI3K inhibitor treatment. For PI3K inhibitor treatment, recipient NSG mice were injected with 5 × 10 4 eGFP + T cells together with CD8-depleted (11447D, Thermo Fisher Scientific) splenocytes from ITK-SYK ;Pdcd1 −/− mice that had been treated with tamoxifen (0.25 mg) 5 days earlier. Five days after transplantation, the NSG mice were given idelalisib (S2226, Selleckchem) or vehicle control (0.5% carboxymethylcellulose, 0.05% Tween-80 in ultra-pure water, C5678 and P4780, Sigma-Aldrich) by oral gavage (10 mg per kg per day) for 5 days a week.
Phosflow. ITK-SYK
CD4-creERT2 mice were intraperitoneally injected with single doses of 2 mg tamoxifen per mouse. Forty-eight hours after injection, singlecell suspensions were generated from the spleens and lymph nodes; then, CD4 + T cells were magnetically purified (130104454, Miltenyi Biotec), and eGFP expression was assessed by flow cytometry. The cells were stimulated with recombinant PD-L1-Fc chimaera protein-coated (758208, BioLegend) microspheres (CS01N, Bangs Laboratories). In brief, streptavidin-coated microspheres were first incubated with a saturating amount of biotinylated anti-human IgG antibody (409302, BioLegend) for 1 h at 37 °C according to the manufacturer's instructions. After extensive washing, these pre-coated microspheres were loaded with either PD-L1-Fc chimaeric protein or control recombinant human Fc fragments (AG714, Merck Group). Efficient coating was ensured by flow cytometry. After 48 h, the cells were fixed in 4% paraformaldehyde followed by methanol permeabilization, stained for p-AKT (S473, 48-9715-42, Thermo Fisher Scientific), p-PKCθ (700043, Thermo Fisher Scientific) and PTEN (9550, Cell Signaling Technology) and assessed by flow cytometry. The following antibodies were used as secondary antibodies: PE-conjugated donkey anti-rabbit IgG (406421, BioLegend) or PE-conjugated goat anti-mouse IgG (405307, BioLegend). Fig. 6b) . The single-cell suspensions were then stained for PTEN, p-AKT and p-PKCθ , and analysed as above.
To assess PTEN, p-AKT and p-PKCθ levels in ITK-SYK
To analyse PTEN, p-AKT and p-PKCθ levels in the PD-1-transduced or mutant PD-1 (YFYF)-transduced T cell NHL samples, the eGFP + FACS-sorted cells were incubated with equal amounts of PD-L1-expressing dendritic cells for 24 h. Afterwards, the cells were fixed and permeabilized, stained for CD3, PTEN, p-AKT and p-PKCθ and then analysed as before.
To analyse the effects of idelalisib (S2226, Selleckchem) on AKT phosphorylation in vivo, 5 × 10 4 lymphoma cells from tamoxifen-treated (0.25 mg) ITK-SYK ;Pdcd1 −/− animals were transferred into NSG recipient mice at day five after tamoxifen injection. Five days later, the NSG mice were orally given a single dose of 10 mg kg −1 idelalisib or vehicle (0.5% carboxymethylcellulose, 0.05% Tween-80 in ultra-pure water). Four hours later, splenic cells were extracted from the NSG mice, fixed and permeabilized in methanol, stained for p-AKT and analysed as above.
In vivo checkpoint inhibition. ITK-SYK
CD4-creERT2 mice were given single injections of tamoxifen (0.25 mg). Beginning 24 h later, the mice were given 200 μ g of anti-PD-L1 antibody (BE0101, Bioxell) or 200 μ g anti-IgG2b (BE0090, Bioxcell) control antibody diluted to 200 μ l with PBS every second day. For the experiments in which the antibody treatment was started during the contraction phase, the ITK-SYK CD4-creERT2 mice were given 200 μ g of anti-PD-L1 (BE0101, Bioxell) or anti-PD-1 (BE0146, Bioxcell) antibody or anti-IgG2b (BE0090, Bioxcell) control antibody diluted to 200 μ l with PBS every third day. In all experiments, the mice were monitored by flow cytometry of the peripheral blood. Histology. All tissues were fixed in 4% formaldehyde and paraffin embedded. Approximately 3-5-μ m-thick sections were cut and stained with haematoxylin and eosin (H&E). Immunohistochemistry was performed on an automated immunostainer (Agilent Technologies) using antibodies against CD3 (CI597C002, DCS), and Ki-67 (ab15580, Abcam). The stained slides were evaluated by an experienced certified pathologist (K.S.) using a BX53 stereomicroscope (Olympus), classified according to the classification of lymphoid neoplasms in mice 40 with respect to the most recent immunohistochemical phenotyping of rodent lymphoid tissues 41 and scanned using a slide scanner (AT-2, Leica Biosystems). Representative images were collected using Aperio Imagescope software (version 12.3, Leica Biosystems). Statistics. All statistical tests were performed using R3.1.3 software (R Foundation for Statistical Computing). In each experiment, the appropriate statistical tests, including non-parametric tests, were used as indicated in the figure legends. Multiple comparisons were performed with ANOVA, Tukey's post hoc test and corrected P values. To assess the correlation between the eGFP maxima and the initial tamoxifen doses (Fig. 1a) , the local maxima (reached on day 4 for the 1 mg and 0.25 mg doses and on day 8 for the 0.05 mg dose of tamoxifen) of the mean eGFP + cell frequencies were used for Pearson coefficient calculations. The association between lymphoma development and initial eGFP + cell frequency (Fig. 1c) was calculated based on the pooled data from two experiments. Fisher's exact test was performed on a 2 × 2 contingency table that was created based on two categorical variables: 'lymphoma development' and 'eGFP maximum > 5% during initial expansion phase' . The variances within the groups in Fig. 1c ; the P values of 'insertions' were used for CIS ranking. The upper tail of the probability density function in Fig. 2b was calculated based on the Poisson rate parameter λ derived from TAPDANCE and the Poisson cumulative distribution function (ppois) in R. No statistical methods were used to predetermine sample size estimates. P < 0.05 was considered statistically significant; for the log-rank test using more than two groups, the α-level was adjusted with Bonferroni's correction. Data availability. RNA-seq data are deposited at the SRA under accession PRJNA362826. All data are available from the corresponding author upon reasonable request. Letter reSeArCH LSL-ITK-SYK ;Rosa26 LSL-PB ; ATP2-H32;CD4-cre lymphoma samples. The cDNA was generated from sorted eGFP + lymphoma cells in which at least one Pdcd1 transposon cassette could be detected. Note that the 5′ piggyBac transposon-specific inverted terminal repeat nucleotide sequence (PB5) can function as a cryptic splice acceptor and a splice donor site. Hence, PB5 may act as a gene trapping sequence by itself 14 . En2SA, exon 2 located mouse En2 splice acceptor; pA, SV40 polyadenylation signal; MSCV, murine stem cell virus long terminal repeat; LunSD, splice donor from exon 1 of mouse Foxf2. Data in b and c are representative from at least 10 analysed mice. The splice junctions in f were amplified from the cDNA of at least eight lymphomas. 
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Letter reSeArCH extended data table 1 | PDCD1 alterations in human lymphomas
Meta-analysis of five published studies containing whole-genome sequencing (WGS) and whole-exome sequencing (WES) data from patients with peripheral T cell lymphoma and cutaneous T cell lymphoma. PDCD1 alterations were observed in 36 out of 158 cases (23%) across the five studies. SNV, single nucleotide variant; TS, targeted sequencing. * All CNAs were focal deletions.
†For CNAs see Fig. 2d and Extended Data Fig. 3a . Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
CNA
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample size estimates.
Data exclusions
Describe any data exclusions.
No data exclusion was performed.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliably reproduced as indicated in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not performed.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not performed.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this Statistics: R3.1.3
